Necrobiosis Lipodica Is a Clinical Feature of Maturity-Onset Diabetes of the Young
- Amanda Stride, MRCP1,
- Paul Lambert, MRCP2,
- A.C. Felix Burden, MD3,
- Peter Mansell, FRCP4,
- Simon Page, FRCP4 and
- Andrew T. Hattersley, DM1
- 1Department of Diabetes and Vascular Medicine, Exeter, U.K.
- 2Department of Diabetes and Metabolism, Medical School Unit, Southmead Hospital, Bristol, U.K.
- 3Heart of Birmingham Diabetes Care, Birmingham, U.K.
- 4Department of Diabetes, Endocrinology and Nutrition, Queens Medical Centre, Nottingham, U.K.
Necrobiosis lipodica (NL) is a recognized feature of diabetes affecting 0.3–1.2% of patients (1,2). It presents with elevated, erythematous lesions (usually on the shins), which typically become atrophic in the center over time. It is most commonly seen in patients with type 1 diabetes, but 7–30% of diabetic patients with NL have type 2 diabetes (1–3). This gives a prevalence of NL of 6.5% in patients with type 1 diabetes and 0.4% in patients with type 2 diabetes. Numerous underlying mechanisms have been proposed, including vascular dysfunction, autoimmunity, and genetic factors (4).
Maturity-onset diabetes of the young (MODY) is a subtype of non-insulin-dependent diabetes characterized by a young age of onset (usually before 25 years), autosomal dominant inheritance, …
